According to the Shapiro–Wilk test, the methylation rates of MAPT at each CpG site and the average rate of all CpG sites were not normally distributed in both AD group and control subjects except for CpG4 methylation rates in the healthy control group. The gene discussed is MAPT; the disease is Alzheimer disease.